Galectin’s NASH Challenges: Paying For Phase III, Carving Market Niche
Executive Summary
Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.
You may also be interested in...
NASH Pipeline Includes Six Candidates That Have Reached Phase III
Our infographic offers a snapshot of the trial endpoints and mechanisms of action of the compounds at the front of the race to treat the enormous NASH market.
Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen
Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.
Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.